Ninety One’s AbbVie ABBV Stock Holding History

Ninety One’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-611	Closed	-$58K	–	132
2018 Q1	$58K	Hold	611	–	–	0.03%	87
2017 Q4	$60K	Hold	611	–	–	0.03%	65
2017 Q3	$54K	Hold	611	–	–	0.03%	65
2017 Q2	$44K	Hold	611	–	–	0.02%	74
2017 Q1	$40K	Hold	611	–	–	0.03%	74
2016 Q4	$38K	Buy	611 +42	+7%	+$2.56K	0.03%	72
2016 Q3	$36K	Buy	569 +79	+16%	+$5.11K	0.02%	83
2016 Q2	$30K	Buy	+490	New	+$29.9K	0.03%	54

Other funds holding ABBV

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Ninety One's ABBV Position: Q2 2018 in Review

Ninety One sold out of AbbVie (ABBV) in Q2 2018, closing a stake of 611 shares — an estimated $58K sold.

Ninety One first reported a position in ABBV in Q2 2016 and held it in 8 quarters. The position peaked at $60K in Q4 2017. 1,996 funds tracked by Wall St. Rank hold ABBV as of Q2 2018.

Ninety One reported no remaining AbbVie position as of Q2 2018 after selling out during the quarter.
Ninety One sold 611 AbbVie shares in Q2 2018, an estimated $58K.
Ninety One first reported a position in AbbVie in Q2 2016 and held it in 8 quarters.
Ninety One's AbbVie position peaked at $60K in Q4 2017.
1,996 funds tracked by Wall St. Rank held AbbVie as of Q2 2018.

Based on Ninety One's 13F filing for Q2 2018, filed 10 Aug 2018.